Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.58 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30808769 | 0.83 | JAK1 (0.50) | JAK1BTKKMT2AL3MBTL1JAK2 | |
| SCHEMBL30808771 | 0.82 | JAK1 (0.52) | JAK1BTKKMT2AL3MBTL1JAK2 | |
| SCHEMBL30808774 | 0.80 | JAK1 (0.53) | JAK1BTKKMT2AL3MBTL1JAK2 | |
| SCHEMBL30808776 | 0.80 | JAK1 (0.51) | JAK1BTKKMT2AL3MBTL1JAK2 | |
| SCHEMBL30808780 | 0.80 | JAK1 (0.51) | JAK1BTKKMT2AL3MBTL1JAK2 | |
| SCHEMBL31376648 | 0.80 | JAK1 (0.62) | JAK1BTKKMT2AL3MBTL1JAK2 | |
| SCHEMBL2294190 | 0.79 | JAK1 (0.90) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL25674741 | 0.79 | JAK1 (0.52) | JAK1BTKKMT2AL3MBTL1JAK2 | |
| SCHEMBL25597839 | 0.78 | JAK1 (0.49) | JAK1BTKKMT2AL3MBTL1JAK2 | |
| SCHEMBL30808790 | 0.78 | JAK1 (0.52) | JAK1BTKKMT2AL3MBTL1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORP (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2023250430-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | JAK1 1037/4885BTK 917/4885KMT2A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.